Doxazosin GITS versus regular doxazosin in benign prostatic hyperplasia. Restoring urine flow and sexual function more easily
Gratzke, P.; Kirby, R.S.
MMW Fortschritte der Medizin 142(26-27): 40
2000
ISSN/ISBN: 1438-3276 PMID: 10929483 Document Number: 520829
Document emailed within 1 workday
Related Documents
Gratzke, P.; Kirby, R.S. 2000: Doxazosin in the gastrointestinal therapeutic system (GITS) and doxazosin standard in patients with benign prostatic hyperplasia. Double-blind trial of efficacy and tolerability Fortschritte der Medizin. Originalien 118(Suppl 2): 83-92Jiménez-García, R.; Anegón, M.; Esteban, J.; Carrasco, P.; Apaolaza, I.; Gil, A. 2003: Safety and effectiveness of replacing standard doxazosin with doxazosin in the gastrointestinal therapeutic system (GITS) formulation in elderly hypertensive patients International Journal of Clinical Practice 57(4): 267-272
Esteban Fuertes, M.; Salinas Casado, J.; Virseda Chamorro, M.; Ramírez Fernández, J.C.; Salomon Moh'd, S.; Luengo Alpuente, S.; Resel Estévez, L. 1997: Doxazosin treatment of disorders of the voiding phase in benign prostatic hyperplasia Archivos Espanoles de Urologia 50(10): 1057-1066
Shao, Q.; Song, J.; Guo, Y.-w.; Lu, W.-c.; Du, L.-d. 2005: Evaluation of sexual function in men with symptomatic benign prostatic hyperplasia Zhonghua Nan Ke Xue 11(7): 505-507
Gu, R.-Z.; Xia, S.-J. 2011: Surgical options for benign prostatic hyperplasia: impact on sexual function and risk factors Zhonghua Nan Ke Xue 17(9): 837-841
Cheng, Y.; Yang, X.; Yu, Y. 2007: Chiral separation of doxazosin and its intermediate by capillary electrophoresis using tetramethylammonium hydroxide to control electroosmotic flow Se Pu 25(4): 478-481
Jonas, U.; Melchior, H.; Rübben, H. 1998: Recommendations for billing alternative therapy of benign prostatic hyperplasia. Laser therapy of benign prostatic hyperplasia Der Urologe. Ausg. a 37(1): 110-111
Bogdanowicz, J.F.; Bentvelsen, F.M.; Oosterom, R.; Schroeder, F.H. 1991: Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia Scandinavian Journal of Urology and Nephrology. Supplementum 138: 97-103
Brannen, G.E.; Coffey, D.S. 1977: Tumor-specific immunity in patients with prostatic adenocarcinoma or benign prostatic hyperplasia Cancer Treatment Reports 61(2): 211-216
Gu, F. 2000: Epidemiological survey of benign prostatic hyperplasia and prostatic cancer in China Chinese Medical Journal 113(4): 299-302
Kletscher, B.A.; Oesterling, J.E. 1995: Prostatic stents. Current perspectives for the management of benign prostatic hyperplasia Urologic Clinics of North America 22(2): 423-430
Granados Loarca, E.A. 1999: Medical treatment of benign prostatic hyperplasia. The efficacy of finasteride depends on prostatic volume Archivos Espanoles de Urologia 52(3): 201-208
Pretlow, T.G.; Whitehurst, G.B.; Pretlow, T.P.; Hunt, R.S.; Jacobs, J.M.; McKenzie, D.R.; McDaniel, H.G.; Hall, L.M.; Bradley, E.L. 1982: Decrease in creatine kinase in human prostatic carcinoma compared to benign prostatic hyperplasia Cancer Research 42(11): 4842-4848
Blanc, M.; Sacrini, A.; Avogadro, A.; Gattamorta, M.; Lazzerini, F.; Gattoni, F.; Cretti, F. 1998: Prostatic volume: suprapubic versus transrectal ultrasonography in the control of benign prostatic hyperplasia La Radiologia Medica 95(3): 182-187
Abdul-Muhsin, H.M.; Jakob, N.J.; McLemore, R.M.; McAdams, S.B.; Humphreys, M.R. 2016: Infectious complications associated with the use of temporary prostatic urethral stents in patients with benign prostatic hyperplasia Canadian Journal of Urology 23(5): 8465-8470
Maygarden, S.J.; Strom, S.; Ware, J.L. 1992: Localization of epidermal growth factor receptor by immunohistochemical methods in human prostatic carcinoma, prostatic intraepithelial neoplasia, and benign hyperplasia Archives of Pathology and Laboratory Medicine 116(3): 269-273
Koval, P.G.; McDiarmid, T. 2000: How effective is doxazosin compared with chlorthalidone in the treatment of hypertension? Journal of Family Practice 49(7): 597-598
Agabiti-Rosei, E.; Muiesan, M.L.; Rizzoni, D.; Zulli, R.; Calebich, S.; Beschi, M.; Castellano, M.; Muiesan, G. 1992: Reduction of left ventricular hypertrophy after longterm antihypertensive treatment with doxazosin Journal of Human Hypertension 6(1): 9-15
Talseth, T.; Westlie, L.; Daae, L. 1990: A long-term study of atenolol and doxazosin in mild and moderate hypertension Journal of Human Hypertension 4(Suppl 3): 39-44
Dominiak, P. 1993: Doxazosin. a postsynaptic alpha 1-adrenergic receptor blocker in therapy of hypertension Der Internist 34(7): 682-687